Conmed CORP 8-K Filing
Ticker: CNMD · Form: 8-K · Filed: Dec 5, 2025 · CIK: 816956
Sentiment: neutral
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-12-05 08:09:31
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by c
Filing Documents
- ea0268554-8k_conmed.htm (8-K) — 25KB
- ea026855401ex99-1_conmed.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-118476.txt ( ) — 207KB
- cnmd-20251205.xsd (EX-101.SCH) — 3KB
- cnmd-20251205_lab.xml (EX-101.LAB) — 33KB
- cnmd-20251205_pre.xml (EX-101.PRE) — 22KB
- ea0268554-8k_conmed_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 5, 2025, CONMED Corporation (the "Company") issued a press release announcing its intent to exit its gastroenterology product lines as part of the Company's portfolio optimization strategy. This includes the termination of its distribution agreement with W.L. Gore & Associates, Inc. for the Gore VIABIL biliary stent effective January 1, 2026 and the expected exit from the remaining products in its gastroenterology product portfolio. A copy of this press release is attached hereto as Exhibit 99.1. The information furnished herewith pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated December 5, 2025, issued by CONMED Corporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 5, 2025 CONMED CORPORATION (Registrant) By: /s/ Todd W. Garner Name: Todd W. Garner Title: Executive Vice President, Finance and Chief Financial Officer 2